Meropenem Dosing Guidelines
For adults with normal renal function, administer meropenem 1 gram intravenously every 8 hours for complicated intra-abdominal infections and 500 mg every 8 hours for complicated skin and skin structure infections (1 gram every 8 hours if Pseudomonas aeruginosa is suspected). 1
Standard Adult Dosing (Normal Renal Function)
Infusion method: Administer as a 15-30 minute intravenous infusion, or as a 3-5 minute bolus injection for 1 gram doses 1
- Complicated intra-abdominal infections: 1 gram IV every 8 hours
- Complicated skin/soft tissue infections: 500 mg IV every 8 hours
- Complicated skin/soft tissue with P. aeruginosa: 1 gram IV every 8 hours
Renal Impairment Dosing Adjustments
Dose reduction is mandatory in patients with creatinine clearance ≤50 mL/min to prevent drug accumulation and potential neurotoxicity 1. The FDA label provides clear guidance:
| Creatinine Clearance | Dose | Interval |
|---|---|---|
| >50 mL/min | Standard dose (500 mg or 1 g) | Every 8 hours |
| 26-50 mL/min | Standard dose | Every 12 hours |
| 10-25 mL/min | Half standard dose | Every 12 hours |
| <10 mL/min | Half standard dose | Every 24 hours |
Important caveat: Patients on continuous renal replacement therapy (CRRT) require different dosing. CRRT increases meropenem clearance approximately 2.1-fold compared to non-dialyzed renal impairment 2. For CRRT patients, 500 mg every 6 hours (as a 3-hour infusion) is recommended 2.
Pediatric Dosing
For children ≥3 months with normal renal function:
| Indication | Dose | Maximum | Interval |
|---|---|---|---|
| Complicated skin/soft tissue | 10 mg/kg | 500 mg | Every 8 hours |
| Complicated intra-abdominal | 20 mg/kg | 1 gram | Every 8 hours |
| Meningitis | 40 mg/kg | 2 grams | Every 8 hours |
For P. aeruginosa skin infections: increase to 20 mg/kg (max 1 gram) every 8 hours 1
For infants <3 months with complicated intra-abdominal infections:
| Age Group | Dose | Interval |
|---|---|---|
| <32 weeks GA, PNA <2 weeks | 20 mg/kg | Every 12 hours |
| <32 weeks GA, PNA ≥2 weeks | 20 mg/kg | Every 8 hours |
| ≥32 weeks GA, PNA <2 weeks | 20 mg/kg | Every 8 hours |
| ≥32 weeks GA, PNA ≥2 weeks | 30 mg/kg | Every 8 hours |
Administer as 30-minute infusion 1
Treatment Duration
Typical treatment courses range from 5-14 days depending on infection severity and clinical response. 3, 4 For complicated intra-abdominal infections, 4-7 days is generally adequate if source control is achieved 3. For complicated skin/soft tissue infections, 7-14 days is standard based on clinical improvement.
Critical Considerations for Optimization
Augmented renal clearance (CrCl >130 mL/min) in critically ill patients may require dose intensification beyond standard regimens 5, 6. Recent pharmacokinetic data demonstrate that patients with CrCl ≥90 mL/min may need 6 grams daily (either 1 gram every 6 hours or 2 grams every 8 hours) to achieve optimal pharmacodynamic targets 5.
For pathogens with MIC ≥4 mg/L, consider extended infusion strategies (3-hour infusion) or continuous infusion to maximize time above MIC 7, 6, 8. Standard intermittent dosing may be insufficient for higher MIC organisms, particularly in critically ill patients.
Common pitfall: The FDA label provides inadequate guidance for hemodialysis and peritoneal dialysis patients 1. Consult nephrology and consider therapeutic drug monitoring in these scenarios. Meropenem is approximately 50% removed by intermittent hemodialysis and should be dosed after dialysis sessions 9.
Seizure risk increases with: renal impairment, CNS pathology, and concurrent use with valproic acid 1. The concomitant use of meropenem with valproic acid is contraindicated due to significant reduction in valproic acid levels, potentially precipitating breakthrough seizures 1.